These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 19455105)

  • 1. Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy.
    Goyenvalle A; Babbs A; van Ommen GJ; Garcia L; Davies KE
    Mol Ther; 2009 Jul; 17(7):1234-40. PubMed ID: 19455105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering exon-skipping vectors expressing U7 snRNA constructs for Duchenne muscular dystrophy gene therapy.
    Goyenvalle A; Davies KE
    Methods Mol Biol; 2011; 709():179-96. PubMed ID: 21194028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering U7snRNA gene to reframe transcripts.
    Goyenvalle A
    Methods Mol Biol; 2012; 867():259-71. PubMed ID: 22454067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy.
    Goyenvalle A; Wright J; Babbs A; Wilkins V; Garcia L; Davies KE
    Mol Ther; 2012 Jun; 20(6):1212-21. PubMed ID: 22354379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exon skipping and duchenne muscular dystrophy therapy: selection of the most active U1 snRNA antisense able to induce dystrophin exon 51 skipping.
    Incitti T; De Angelis FG; Cazzella V; Sthandier O; Pinnarò C; Legnini I; Bozzoni I
    Mol Ther; 2010 Sep; 18(9):1675-82. PubMed ID: 20551908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
    Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ
    J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping.
    Brun C; Suter D; Pauli C; Dunant P; Lochmüller H; Burgunder JM; Schümperli D; Weis J
    Cell Mol Life Sci; 2003 Mar; 60(3):557-66. PubMed ID: 12737315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
    Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric adeno-associated virus/antisense U1 small nuclear RNA effectively rescues dystrophin synthesis and muscle function by local treatment of mdx mice.
    Denti MA; Rosa A; D'Antona G; Sthandier O; De Angelis FG; Nicoletti C; Allocca M; Pansarasa O; Parente V; Musarò A; Auricchio A; Bottinelli R; Bozzoni I
    Hum Gene Ther; 2006 May; 17(5):565-74. PubMed ID: 16716113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping.
    Goyenvalle A; Babbs A; Wright J; Wilkins V; Powell D; Garcia L; Davies KE
    Hum Mol Genet; 2012 Jun; 21(11):2559-71. PubMed ID: 22388933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells.
    De Angelis FG; Sthandier O; Berarducci B; Toso S; Galluzzi G; Ricci E; Cossu G; Bozzoni I
    Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9456-61. PubMed ID: 12077324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy.
    Barbash IM; Cecchini S; Faranesh AZ; Virag T; Li L; Yang Y; Hoyt RF; Kornegay JN; Bogan JR; Garcia L; Lederman RJ; Kotin RM
    Gene Ther; 2013 Mar; 20(3):274-82. PubMed ID: 22551778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in.
    Popplewell L; Koo T; Leclerc X; Duclert A; Mamchaoui K; Gouble A; Mouly V; Voit T; Pâques F; Cédrone F; Isman O; Yáñez-Muñoz RJ; Dickson G
    Hum Gene Ther; 2013 Jul; 24(7):692-701. PubMed ID: 23790397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting
    Wein N; Dunn DM; Waldrop MA; Gushchina LV; Frair EC; Weiss RB; Flanigan KM
    Hum Gene Ther; 2021 Nov; 32(21-22):1346-1359. PubMed ID: 34060935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping.
    Bish LT; Sleeper MM; Forbes SC; Wang B; Reynolds C; Singletary GE; Trafny D; Morine KJ; Sanmiguel J; Cecchini S; Virag T; Vulin A; Beley C; Bogan J; Wilson JM; Vandenborne K; Kornegay JN; Walter GA; Kotin RM; Garcia L; Sweeney HL
    Mol Ther; 2012 Mar; 20(3):580-9. PubMed ID: 22146342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M; Takeshima Y; Nishio H
    Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
    Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy.
    Le Hir M; Goyenvalle A; Peccate C; Précigout G; Davies KE; Voit T; Garcia L; Lorain S
    Mol Ther; 2013 Aug; 21(8):1551-8. PubMed ID: 23752313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.